zavegepant
Selected indexed studies
- Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. (Lancet Neurol, 2023) [PMID:36804093]
- Zavegepant: First Approval. (Drugs, 2023) [PMID:37227596]
- Zavegepant. (, 2012) [PMID:40009707]
_Worker-drafted node — pending editorial review._
Connections
zavegepant is a side effect of
Sources
- Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. (2025) pubmed
- Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. (2023) pubmed
- Zavegepant: First Approval. (2023) pubmed
- Zavegepant. (2012) pubmed
- Zavegepant Intranasal Spray for Migraines. (2024) pubmed
- Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. (2022) pubmed
- Zavegepant. (2006) pubmed
- Intranasal zavegepant for the acute treatment of migraine. (2024) pubmed
- Zavegepant nasal spray for the acute treatment of migraine: A meta analysis. (2023) pubmed
- Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (2024) pubmed